Factors influencing pharmacy services in opioid substitution treatment

Drug and Alcohol Review

Volumn 32, Issue 4, 2013, Pages 426-434

  Chaar, Betty B ^a   Wang, Holly ^a   Day, Carolyn A ^b   Hanrahan, Jane R ^a   Winstock, Adam R ^c   Fois, Romano ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Australian pharmacist; Disproportionate distribution of clientele; Pharmacy OST service; Professionals' moral responsibility; Providers' and non providers' perspective

Indexed keywords

ARTICLE; AUSTRALIA; AUSTRALIAN PHARMACIST; DISPROPORTIONATE DISTRIBUTION OF CLIENTELE; FEMALE; HEALTH CARE DELIVERY; HEALTH PERSONNEL ATTITUDE; HEROIN DEPENDENCE; HUMAN; MALE; OPIATE SUBSTITUTION TREATMENT; PHARMACIST; PHARMACY; PHARMACY OST SERVICE; PROFESSIONALS' MORAL RESPONSIBILITY; PROVIDERS' AND NON-PROVIDERS' PERSPECTIVE; PSYCHOLOGICAL ASPECT; UTILIZATION REVIEW;

AUSTRALIAN PHARMACIST; DISPROPORTIONATE DISTRIBUTION OF CLIENTELE; PHARMACY OST SERVICE; PROFESSIONALS' MORAL RESPONSIBILITY; PROVIDERS' AND NON-PROVIDERS' PERSPECTIVE;

ATTITUDE OF HEALTH PERSONNEL; AUSTRALIA; COMMUNITY PHARMACY SERVICES; FEMALE; HEALTH SERVICES ACCESSIBILITY; HEROIN DEPENDENCE; HUMANS; MALE; OPIATE SUBSTITUTION TREATMENT; PHARMACISTS;

EID: 84879882095     PISSN: 09595236     EISSN: 14653362     Source Type: Journal    
DOI: 10.1111/dar.12032     Document Type: Article

References (45)

1. Caldicott DG, Duff C. Reducing drug-related harm: Australia leads the way. MJA 2005;182:140-141.
2. Chaar BB, Hanrahan JR, Day C. Provision of opioid substitution therapy services in Australian pharmacies. Australas Med J 2011;4:210-216.
3. Ross JE, Teesson M, Darke S, etal. The characteristics of heroin users entering treatment: findings from the Australian treatment outcome study (ATOS). Drug Alcohol Rev 2005;24:411-418.
4. Rowe JA. Raw deal? Impact on the health of consumers relative to the cost of pharmacotherapy. Melbourne: Centre for Applied Social Research (RMI T) for the Salvation Army Research and Advocacy Unit, 2008. Available at: http://www.salvationarmy.org.au/Global/News%20and%20Media/Reports/2008/raw-deal-book.pdf (accessed February 2013).
5. National Drug Strategy. National policy on methadone treatment. Canberra: Commonwealth Department of Health and Family Services, 1998. [3 February 2011]; Available at: http://www.health.gov.au/internet/main/publishing.nsf/Content/phd-illicit-methadone-treatment (accessed February 2013).
6. Fraser S, Valentine K, Treloar C, Macmillan K. Methadone maintenance treatment in New South Wales and Victoria: takeaways, diversion and other key issues. Sydney: National Centre in HIV Social Research; The University of New South Wales, 2007. Available at: http://nchsr.arts.unsw.edu.au/media/File/Methadone2007keyfindings.pdf (accessed February 2013).
7. Opioid Substitution Program Resource Manual. Standard 3-delivery of health programs and services. Sydney: The Pharmacy Guild of Australia (New South Wales Branch), 2011:66. Available at: http://www.guild.org.au/iwov-resources/documents/NSW_Branch/Professional%20Services/Dependency%20Care/Pharmacotherapy/Opioid%20Substitution%20Program-Web.pdf (accessed February 2013).
8. Feyer A-M, Mattick RP, Schulman C, Jessop R, Solomon J, Pyper D. A national funding model for pharmacotherapy treatment for opioid dependence in community pharmacy. Canberra: The Pharmacy Guild of Australia and PricewaterhouseCoopers, 2010.
9. Lawrinson P, Roche A, Terao H, Le PP. Dispensing opioid substitution treatment: practices, attitudes and intentions of community-based pharmacists. Drug Alcohol Rev 2008;27:47-55.
10. Chalmers J, Ritter A, Heffernan M, McDonnell G. Modelling pharmacotherapy maintenance in Australia: exploring affordability, availability, accessibility and quality using a systems dynamic modelling approach. Sydney: National Drug and Alcohol Research Centre, 2009.
11. Deering DEA, Sheridan J, Sellman JD, etal. Consumer and treatment provider perspectives on reducing barriers to opioid substitution treatment and improving treatment attractiveness. Addict Behav 2011;36:636-642.
12. Fleming GF, McElnay JC, Hughes CM, Sheridan J, Strang J. The role of the community pharmacist in drug abuse: a comparison of service provision between Northern Ireland and England/Wales. Pharm World Sci 2001;23:13-16.
13. Mackie CA, Healey AM, Roberts K, Ryder S. A comparison of community pharmacy methadone services between Dublin and Glasgow: (1) Extent of service provision in 1997/1998 and views of pharmacists on existing provision and future service developments. J Subst Use 2004;9:235-251.
14. Matheson C, Bond CM, Hickey F. Prescribing and dispensing for drug misusers in primary care: current practice in Scotland. Fam Pract 1999;16:375-379.
15. Matheson C, Bond CM, Mollison J. Attitudinal factors associated with community pharmacists' involvement in services for drug misusers. Addiction 1999;94:1349-1359.
16. Matheson C, Bond CM, Pitcairn J. Community pharmacy services for drug misusers in Scotland: what difference does 5 years make? Addiction 2002;97:405-411.
17. Matheson C, Bond CM, Tinelli M. Community pharmacy harm reduction services for drug misusers: national service delivery and professional attitude development over a decade in Scotland. J Public Health (Oxf) 2007;29:350-357.
18. McBride AF, Pates R, Psy DC, Li S, Ramadan R. Service provisions for drugs users: a survey of community pharmacies in a South Wales health authority. Pharm J 2001;267:820-823.
19. Rosenblom EK, Taylor KMG, Harding G. Service provision to opiate misusers from pharmacies-an exploratory study. J Soc Adm Pharm 2003;20:110-116.
20. Sheridan J, Cronin F. Supervised self-administration of methadone at community pharmacies: the introduction of a new service. Pharm J 2002;268:471-474.
21. Sheridan J, Strang J. Community pharmacy in Wales: 1995 data on HIV prevention and drug misuse services. J Ment Health 1998;7:203-210.
22. Sheridan J, Strang J, Taylor C, Barber N. HIV prevention and drug treatment services for drug misusers: a national study of community pharmacists' attitudes and their involvement in service specific training. Addiction 1997;92:1737-1748.
23. Bonnet N, Beauverie P, Gaudoneix-Taieb M, etal. Changes in pharmacists practices (1996-2000) related to harm reduction policy (condoms, injecting equipment, methylmorphine) and maintenance therapy delivery (buprenorphine, methadone). Ann Med Interne (Paris) 2001;152 (Suppl 7):15-20.
24. Diez Macaya J, Ramos E, Blas C, etal. Evaluation of the methadone maintenance program in Bizkaia in 2003, methodological aspects. Pharm Care Esp 2006;8:72-80.
25. Jeantaud I, Haramburu F, Begaud B. Maintenance treatment for opioid dependence: survey of community pharmacies in south-western France. Therapie 1999;54:251-255.
26. Raisch DW, Fudala PJ, Saxon AJ, etal. Pharmacists' and technicians' perceptions and attitudes toward dispensing buprenorphine/naloxone to patients with opioid dependence. J Am Pharm Assoc 2003;45:23-32.
27. The Pharmacy Guild of Australia. Substance abuse in Australian communities-pharmacy guild of Australia submission to the inquiry of the house of representative standing Committee on Family and Community Affairs on the social and economic costs of substance abuse. Canberra: The Pharmacy Guild of Australia, 2000. Available at: www.aph.gov.au/Parliamentary_Business/Committees/House_of_Representatives_Committees?url=/fca/subabuse/sub151.pdf (accessed February 2013).
28. The Pharmacy Guild of Australia. Submission to the productivity Commission Health workforce study. Canberra: The Pharmacy Guild of Australia, 2005. Available at: http://www.pc.gov.au/__data/assets/pdf_file/0012/11442/sub165.pdf (accessed February 2013).
29. Australian Government Department of Health and Ageing (DoHA). National pharmacotherapy policy for people dependent on Opioids. Canberra: Australian Government Department of Health and Ageing, 2007. Available at: http://www.nationaldrugstrategy.gov.au/internet/drugstrategy/publishing.nsf/content/pharmacotherapy (accessed February 2013).
30. Ritter A, Chalmers J. The many sides to the Australian opioid pharmacotherapy maintenance system. Canberra: Australian National Council on Drugs, 2009. [Report No. 9781877018213]. Available at: http://www.ancd.org.au/images/PDF/Researchpapers/rp18_polygon.pdf?phpMyAdmin=rGQ2XkOOsKjMp24r2sFwuVc5ibb (accessed February 2013).
31. Australian Institute of Health and Welfare (AIHW). National opioid pharmacotherapy statistics annual data collection. Canberra: Australian Institute of Health and Welfare (AIHW), 2009:40. Available from: http://www.aihw.gov.au/publication-detail/?id=6442468365&tab=2 (accessed February 2013).
32. Australian Institute of Health and Welfare (AIHW). (2010) National Opioid Pharmacotherapy Statistics Annual Data Collection. Canberra: 2010.
33. Nielsen S, Dietze P, Dunlop A, Muhleisen P, Lee N, Taylor D. Buprenorphine supply by community pharmacists in Victoria, Australia: perceptions, experiences and key issues identified. Drug Alcohol Rev 2007;26:143-151.
34. Winstock AR, Lea T, Sheridan J. Problems experienced by community pharmacists delivering opioid substitution treatment in New South Wales and Victoria, Australia. Addiction 2010;105:335-342.
35. Winstock AR, Lea T, Sheridan J. What is diversion of supervised buprenorphine and how common is it? J Addict Dis 2009;28:269-278.
36. Fossey E, Harvey C, Dermott FM, Davidson L. Understanding and evaluating qualitative research. Aust N Z J Psychiatry 2002;36:717-732.
37. Berbatis CG, Sunderland VB, Joyce A, Bulsara M, Mills C. Enhanced pharmacy services, barriers and facilitators in Australia's community pharmacies: Australia's National Pharmacy Database Project. Int J Pharm Pract 2007;15:185-191.
38. Koutroulis GY, Kutin JJ, Ugoni AM, etal. Pharmacists' provision of methadone to intoxicated clients in community pharmacies, Victoria, Australia. Drug Alcohol Rev 2000;19:299-308.
39. Winstock A, Lea T, Molan J. New South Wales community pharmacy practice survey: SWAT Report 2. Sydney: National Drug and Alcohol Research Centre, University of New South Wales, 2008. [3 February 2011]. Available at: http://beta.guild.org.au/uploadedfiles/Research_and_Development_Grants_Program/Projects/2001-056_fr.pdf (accessed February 2013).
40. Berbatis CG, Sunderland VB, Bulsara M, Mills C. Australia's community pharmacy survey-national pharmacy database project. The Commonwealth Department of Health and Ageing and The Pharmacy Guild of Australia; 2003. [3 February 2011]. Available at: http://beta.guild.org.au/uploadedfiles/Research_and_Development_Grants_Program/Projects/2001-056_fr.pdf (accessed February 2013).
41. Luty J, Kumar P, Stagias K. Stigmatised attitudes in independent pharmacies associated with discrimination towards individuals with opioid dependence. Psychiatrist 2010;34:511-514.
42. Lawrie T, Matheson C, Bond CM, Roberts KAY. Pharmacy customers' views and experiences of using pharmacies which provide drug misuse services. Drug Alcohol Rev 2004;23:195-202.
43. Watson T, Hughes C. Pharmacists and harm reduction: a review of current practices and attitudes. Can Pharm J 2012;145:124-127.
44. Walker M. Best practice guidance for commissioners and providers of pharmaceutical services for drug users. London: Royal Pharmaceutical Society of Great Britain, 2006. Available at: http://www.nta.nhs.uk/uploads/nta_best_practice_pharma_services_for_drug_users_pharmguide06.pdf (accessed February 2013).
45. Royal Pharmaceutical Society of Great Britain. Code of ethics for pharmacists and pharmacy technicians. 2007. http://www.rpsgb.org (accessed February 2013).